BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Alkermes (ALKS) Chairman Richard Pops to Resume Role of CEO


9/11/2009 8:29:53 AM

Bookmark and Share

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alkermes, Inc. today announced that Richard Pops will assume the duties of President and Chief Executive Officer, effective immediately. Mr. Pops, who will retain his duties as Chairman of the Board, will replace David Broecker who is leaving the company.

“I am enthusiastic about returning to the role of Chief Executive Officer. Alkermes is an exciting company and David leaves it in a strong position as we prepare for the approval of exenatide once weekly, complete the VIVITROL® pivotal study to expand the label into the opioid dependence indication and expand our pipeline of innovative medicines,” said Richard Pops. “I look forward to leading Alkermes as we develop medications that result in value to patients, as well as to our shareholders, in the years to come.”

Richard Pops, 47, served as Chief Executive Officer of Alkermes from February 1991 through April 2007. In April 2007, he assumed the role of Chairman of the Board along with continuing to remain actively involved as a full-time employee of the company in charge of strategy. Under his leadership, Alkermes grew from a privately held company with 25 employees to a publicly traded biotechnology company with more than 500 employees and two commercial products.

Mr. Broecker has resigned, effective immediately, from his position as President and Chief Executive Officer and as a member of the Board of Directors.

“On behalf of the Board and Alkermes employees, I would like to thank David Broecker for his numerous contributions to our company over the past eight years. We wish him much success in the future,” commented Pops.

About Alkermes

Alkermes, Inc. is a fully integrated biotechnology company committed to developing innovative medicines to improve patients' lives. Alkermes developed, manufactures and commercializes VIVITROL® for alcohol dependence and manufactures RISPERDAL® CONSTA® for schizophrenia and bipolar I disorder. Alkermes' robust pipeline includes extended-release injectable, pulmonary and oral products for the treatment of prevalent, chronic diseases, such as central nervous system disorders, addiction and diabetes. Headquartered in Cambridge, Massachusetts, Alkermes has research facilities in Massachusetts and a commercial manufacturing facility in Ohio.

VIVITROL® is a registered trademark of Alkermes, Inc. and RISPERDAL® CONSTA® is a registered trademark of Janssen-Cilag group of companies.

Contacts

Alkermes, Inc. For Investors: Rebecca Peterson, 617-583-6378 or For Media: Jennifer Snyder, 617-583-6166

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES